Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer. The...
16 KB (1,299 words) - 19:06, 22 August 2023
in 2010. In August 2011 Puma licensed two drug candidates from Pfizer: neratinib (PB272) and an analog (PB357) to serve as a backup candidate.: 6, 23 ...
9 KB (798 words) - 07:15, 29 February 2024
afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib...
5 KB (232 words) - 10:23, 8 March 2024
1-1% frequency) Keratitis Interstitial lung disease Like lapatinib and neratinib, afatinib is a protein kinase inhibitor that also irreversibly inhibits...
14 KB (1,126 words) - 18:50, 30 November 2023
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
31 KB (3,413 words) - 23:30, 21 June 2024
anti-HER2 therapeutics are also tyrosine kinase inhibitors (Lapatinib, Neratinib, and Tucatinib) and antibody-drug conjugates (ado-trastuzumab emtansine...
43 KB (4,651 words) - 05:18, 13 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
121 KB (13,799 words) - 06:42, 1 July 2024
expected to lead to a wider therapeutic index. The pan-ErbB inhibitor Neratinib was approved in the US in 2017 and in the EU in 2018 for the extended...
20 KB (2,061 words) - 05:47, 29 November 2023
co-opted to promote cancer cell survival and metastasis. In breast cancers, neratinib, a novel pan-ERBB inhibitor, is able to downmodulate the amount of HER2...
62 KB (6,542 words) - 00:51, 20 May 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
13 KB (1,177 words) - 18:50, 10 July 2024
margetuximab can also prolong survival, as can HER2 inhibitors lapatinib, neratinib, or tucatinib. Certain therapies are targeted at those whose tumors have...
129 KB (14,628 words) - 14:31, 8 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
74 KB (6,565 words) - 05:35, 13 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
16 KB (1,784 words) - 04:08, 6 January 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
92 KB (8,667 words) - 19:29, 28 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
150 KB (15,741 words) - 10:52, 27 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
25 KB (2,085 words) - 03:15, 6 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
10 KB (661 words) - 04:10, 26 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
45 KB (5,341 words) - 08:28, 10 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
20 KB (1,543 words) - 06:38, 10 March 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
108 KB (12,653 words) - 16:16, 10 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
21 KB (1,808 words) - 04:37, 20 March 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
9 KB (1,081 words) - 04:46, 16 June 2022
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
6 KB (460 words) - 19:16, 8 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
40 KB (4,580 words) - 05:24, 3 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
17 KB (1,735 words) - 03:22, 28 February 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
27 KB (3,071 words) - 04:54, 3 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
16 KB (1,122 words) - 03:21, 24 April 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
29 KB (2,699 words) - 00:43, 10 February 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
68 KB (5,993 words) - 00:47, 13 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
24 KB (2,877 words) - 10:08, 2 June 2024